3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Healthy Participants
5
Neoplasms
3
Solid Tumor, Adult
2
Carcinoma, Non-Small-Cell Lung
2
cMET-dysregulated Advanced Solid Tumors
1
TP53 Y220C Mutation
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Pain
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Healthy Volunteers
1
Healthy Adult Participants
1
Healthy
1
Drug-drug Interaction,SHR3680
1
Colorectal Neoplasms
1
Chronic Cough
1
Advanced Solid Tumor
1
Advanced Solid Malignancies
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Cyclophosphamide
6
tazemetostat
5
fludarabine
4
pembrolizumab
2
soblidotin
1
reolysin
1
pazopanib
1
drozitumab
1
cixutumumab
1
atezolizumab
1
anlotinib
1
Tablets
1
Rosuvastatin Calcium
1
Rifampin
1
Ramucirumab
1
Radiation
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Itraconazole
1
Injections
1
Immunotherapy, Adoptive
1
Immunotherapy
1
Imatinib Mesylate
1
Ifosfamide
1
Gemcitabine
1
Drug Therapy
1
Doxorubicin
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma, Synovial
×
Rosuvastatin Calcium
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled